Chapter 7: Cardiac and Vascular Risk

Cardiovascular disease prevention depends fundamentally on understanding and managing the risk factors that drive coronary heart disease, stroke, and peripheral vascular disease. The Framingham Heart Study, initiated in 1948 and tracking multiple generations of participants, established the evidence base for identifying which characteristics predict these major cardiovascular events and enabled development of clinical risk assessment tools still used today. Coronary heart disease risk factors divide into modifiable categories such as hypertension, dyslipidemia, diabetes, and metabolic syndrome alongside nonmodifiable factors including age, sex, ethnicity, and family history; life habit factors like smoking, obesity, physical inactivity, and poor diet; and emerging risk factors such as elevated homocysteine, inflammatory markers, and left ventricular hypertrophy. Patients with existing cardiovascular disease or conditions conferring equivalent risk, such as type 2 diabetes, face greater than 20 percent probability of a major cardiac event within ten years and require intensive therapeutic intervention. Stroke, representing the leading cause of long-term disability, occurs as either ischemic blockage in 87 percent of cases or hemorrhagic bleeding in 13 percent, with hypertension being the strongest modifiable predictor for both types; atrial fibrillation substantially elevates stroke risk, quantifiable through the CHADS2 scoring system, while prior transient ischemic attack or stroke represents the most powerful nonmodifiable risk indicator. Peripheral vascular disease affects 12 to 14 percent of the population and presents as intermittent claudication or critical limb ischemia, with diabetes conferring three to fourfold increased risk and tobacco use creating 2.5 to 3 times greater likelihood of disease development; symptomatic peripheral vascular disease carries 30 percent mortality within five years primarily from myocardial infarction or stroke. Risk stratification models using Framingham data enable clinicians to calculate ten-year probability estimates for each condition, allowing treatment decisions to match individual risk levels, while racial, ethnic, and gender disparities in cardiovascular disease prevalence underscore the importance of tailored public health approaches and aggressive management of modifiable risk factors across diverse populations.